Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 7 of the 30 sources its claims cite were checked for support.
Abstract
BACKGROUND: mRNA with volanesorsen led to decreased plasma apolipoprotein C-III and triglyceride levels. METHODS: We conducted a phase 3, double-blind, randomized 52-week trial to evaluate the safety and effectiveness of volanesorsen in 66 patients with familial chylomicronemia syndrome. Patients were randomly assigned, in a 1:1 ratio, to receive volanesorsen or placebo. The primary end point was the percentage change in fasting triglyceride levels from baseline to 3 months. RESULTS: Patients receiving volanesorsen had a decrease in mean plasma apolipoprotein C-III levels from baseline of 25.7 mg per deciliter, corresponding to an 84% decrease at 3 months, whereas patients receiving placebo had an increase in mean plasma apolipoprotein C-III levels from baseline of 1.9 mg per deciliter, corresponding to a 6.1% increase (P<0.001). Patients receiving volanesorsen had a 77% decrease in mean triglyceride levels, corresponding to a mean decrease of 1712 mg per deciliter (19.3 mmol per liter) (95% confidence interval [CI], 1330 to 2094 mg per deciliter [15.0 to 23.6 mmol per liter]), whereas patients receiving placebo had an 18% increase in mean triglyceride levels, corresponding to an increase of 92.0 mg per deciliter (1.0 mmol per liter) (95% CI, -301.0 to 486 mg per deciliter [-3.4 to 5.5 mmol per liter]) (P<0.001). At 3 months, 77% of the patients in the volanesorsen group, as compared with 10% of patients in the placebo group, had triglyceride levels of less than 750 mg per deciliter (8.5 mmol per liter). A total of 20 of 33 patients who received volanesorsen had injection-site reactions, whereas none of the patients who received placebo had such reactions. No patients in the placebo group had platelet counts below 100,000 per microliter, whereas 15 of 33 patients in the volanesorsen group had such levels, including 2 who had levels below 25,000 per microliter. No patient had platelet counts below 50,000 per microliter after enhanced platelet-monitoring began. CONCLUSIONS: Volanesorsen lowered triglyceride levels to less than 750 mg per deciliter in 77% of patients with familial chylomicronemia syndrome. Thrombocytopenia and injection-site reactions were common adverse events. (Funded by Ionis Pharmaceuticals and Akcea Therapeutics; APPROACH Clinical Trials.gov number, NCT02211209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 15 Not checked · 60 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These data show that volanesorsenmediated lowering of apolipoprotein C-III effectively enhances clearance of triglyceride-rich lipoproteins in patients without LPL activity.27”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Discussion
What the sources say
- Partly supportedcites [27] matched to “ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors” (2016) sourceExperimental — accuracy not yet measured
The Introduction (p. n/a) states that volanesorsen 'dramatically lowered elevated plasma TG levels in patients who have genetic defects in LPL (familial chylomicronemia syndrome [FCS])' and that, despite the absence of a placebo control group, 'this finding suggests that ApoC-III impairs TG clearance predominantly in an LPL-independent fashion'; the Discussion adds that their mouse data are 'consistent with the recent observation that targeting of ApoC-III effectively reduces plasma TGs in LPL-deficient patients'. So the enhanced-clearance-in-LPL-deficient-patients reading is present, but the source hedges it as a suggestion inferred from TG lowering (clearance itself was measured only in mice) and explicitly flags the uncontrolled design; the Discussion also notes the FCS subjects had a mutated LPL with possible residual activity rather than a strict absence. The citing sentence's unhedged 'these data show ... effectively enhances clearance' therefore overstates what this source attributes to the trial. (LLM, conf=0.72)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“The APPROACH trial showed that volanesorsenmediated lowering of plasma apolipoprotein C-III levels in patients with familial chylomicronemia syndrome effectively lowered plasma triglycerides below the threshold of 750 to 880 mg per deciliter”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Discussion
What the sources say
- Not checked yetcites [6] matched to “Chylomicronaemia–current diagnosis and future therapies” (2015) source
- Could not verifycites [21] matched to “National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2” (2015) sourceExperimental — accuracy not yet measured
Our copy of the NLA Part 2 recommendations contains no mention of volanesorsen, apolipoprotein C-III as a therapeutic target, or the APPROACH trial (searched: 'volanesorsen APPROACH trial apolipoprotein C-III familial chylomicronemia syndrome', 'apolipoprotein C-III antisense oligonucleotide new therapies', 'severe hypertriglyceridemia pancreatitis threshold'). The closest passages cover only established therapy for very high TG — the 'Dietary considerations for management of hypertriglyceridemia' and 'Targets of lifestyle therapies' sections set the pancreatitis-prevention goal at lowering TG to <500 mg/dL (noting chylomicronemia is often present at ≥750 mg/dL), and the 'Non-statin recommendations' / 'Fibrates' sections discuss fenofibrate and prescription omega-3s — so nothing here speaks to the trial result attributed to this source. Our copy is also flagged as truncated, so the decisive text may be missing. (LLM, conf=0.72)
- Could not verifycites [22] matched to “Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline” (2012) sourceExperimental — accuracy not yet measured
Our copy of the 2012 Endocrine Society guideline contains no mention of volanesorsen, the APPROACH trial, or an antisense apoC-III oligonucleotide (searched: 'volanesorsen APPROACH trial apolipoprotein C-III antisense', 'antisense oligonucleotide apoC-III inhibitor', '750 mg/dl triglyceride threshold'); apoC-III appears only in pathophysiology/kinetics references. Nor does it give a 750-880 mg/dl pancreatitis threshold: the Chylomicronemia syndrome section states pancreatitis risk 'markedly increases with very severe triglyceride levels above 2000 mg/dl' and 'can be prevented by maintaining triglyceride levels below 1000 mg/dl', and the Fibrates section sets a treatment goal of <1000 mg/dl. The trial result attributed here is therefore not addressed by this source at all (the guideline predates the APPROACH trial), so the claim cannot be checked against it. (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“findings that support the hypothesis that apolipoprotein C-III also inhibits an LPL-independent pathway of triglyceride-rich lipoprotein clearance.16”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > F
What the sources say
- Supportedcites [16] matched to “Targeting APOC3 in the familial chylomicronemia syndrome” (2014) source
The Discussion says the study's findings suggest that APOC3 regulates triglyceride-rich lipoprotein metabolism through LPL-independent pathways. The Figure 2 caption states more specifically that APOC3 has an inhibitory role in that pathway, matching the citing sentence's hypothesis. (LLM, conf=0.94)
hedgedstates a causen = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Three other patients with lesser grades (grade 1 or 2) of decreased platelet counts were withdrawn from the trial because of concerns on the part of the site investigators.”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Safety
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fourteen patients assigned to volanesorsen, as compared with 2 patients assigned to placebo, did not complete the 52-week trial”
- Also stated in: § 541 · plain
“Fourteen patients in the volanesorsen group discontinued the trial: 9 because of adverse events that occurred during treatment (including 5 who had decreases in platelet counts and 4 because of other drug-related side effects), and 5 primarily because of issues related to requirements of the protocol.”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Safety
plainn = 14- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 541 · plain
22 more claims
Create a free account to see all 79 claims and to verify the 23 references still open.
- Probably not a substantial claim. 21
- It may state two separate claims as one. 38
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our findings are consistent with the observations that LDL cholesterol levels are typically very low (<20 mg per deciliter [0.52 mmol per liter]) and total apolipoprotein B levels are within the low-to-normal range in persons with familial chylomicronemia syndrome. 25”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a previous trial involving patients with familial chylomicronemia syndrome, the administration of volanesorsen at a weekly dose of 300 mg per deciliter over a 3-month period was accompanied by reductions in apolipoprotein C-III and triglyceride levels of 84% and 77%, respectively, 25”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While APPROACH was not powered to detect clinical endpoints, exploratory analyses showed a meaningful reduction in pancreatitis episodes among patients who achieved sustained TG levels below 500 mg/dL— considered by some to be a threshold for pancreatitis risk [44].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“its safety profile, particularly the high incidence of thrombocytopenia, has limited broader clinical adoption [115]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [115]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reduced platelet counts below 100 000 per microliter was a common adverse event in the volanesorsen group (15 of 33 patients, two patients with levels < 25 000 per microliter).74”
From Clinical review on triglycerides (2020) · cites this paper as [74]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Abstract
“15 of 33 patients in the volanesorsen group had such levels”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Safety
“confirmed nadir levels below 100,000 per microliter were observed in 16 patients (48%) who received volanesorsen”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“1933 mg per deciliter [22.5 mmol per liter]”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Secondary Efficacy End Points
Reported 22.5 · recomputed 21.82357
Citations
Cites
Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., Tsiotos, G. G., & Vege, S. S. (2013) · Gut · doi:10.1136/gutjnl-2012-302779 · Cited by 7,187
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Self-citationTargeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Self-citationIssues in Hypertriglyceridemic Pancreatitis: An Update
Scherer, J., Singh, V. P., Pitchumoni, C. S., & Yadav, D. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000436438.60145.5a · Cited by 475
Current knowledge of hypertriglyceridemic pancreatitis
Valdivielso, P., Ramírez-Bueno, A., & Ewald, N. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.08.008 · Cited by 439
Chylomicronaemia–current diagnosis and future therapies
Brahm, A. J., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.26 · Cited by 356
Biochemistry and pathophysiology of intravascular and intracellular lipolysis
Young, S. G., & Zechner, R. (2013) · Genes & Development · doi:10.1101/gad.209296.112 · Cited by 348
Research works printed but not linked: 1
- Brunzell JD Deeb SS. Familial lipoprotein lipase deficiency apo CII deficiency and hepatic lipase deficiency. In: Scriver CR Beaudet AL Sly WS et al. eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill 2000:2789-816.
Cited by
Items 301–400 of 673
Approach to the Adult Patient with Chylomicronemia
Hegele, R. A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf701 · Cited by 14
Tomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 11
High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?
von Eckardstein, A. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_536 · Cited by 13
Management of Mild-to-Moderate Hypertriglyceridemia
Pulipati, V. P., Brinton, E. A., & Hatipoğlu, B. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.07.003 · Cited by 12
Lipid management to mitigate poorer postkidney transplant outcomes
Skulratanasak, P., & Larpparisuth, N. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000841 · Cited by 10
“However, an injection-site reaction is common (61%) caused by relatively high doses [59].”
BackgroundNiknejad, N., Fox, D., Burwinkel, J. L., Zarrin‐Khameh, N., Cho, S., Soriano, A., Cast, A. E., Lopez, M. F., Huppert, K. A., Rigo, F., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000380 · Cited by 13
“[39,40] However, to our knowledge, no ASO-based therapy has been approved for clinical use in a genetic childhood disease affecting liver development.”
Pedro‐Botet, J., Ascaso, J. F., Blasco, M., Brea, Á., Rodríguez, Á. D., Hernández‐Mijares, A., Pintó, X., & Millán, J. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.12.003 · Cited by 19
“…efectos beneficiosos del volanesorsen como complemento a la dieta en adultos con síndrome de quilomicronemia familiar gené-ticamente confirmado, revelando el brazo de tratamiento activo una disminución a los 3 meses del 84% en los niveles de apo C-III y del 77% en los niveles de triglicéridos 50 .”
BackgroundMayerhofer, C., Speckmann, C., Kapp, F., Teufel‐Schäfer, U., Kluwe, W., Schneider, J., & Flotho, C. (2020) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2020.1756999 · Cited by 9
Recent advances and emerging therapies in management of dyslipidemias
Pulipati, V. P., & Davidson, M. H. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.08.007 · Cited by 9
Beyond the Guidelines: Perspectives on Management of Pediatric Patients with Hypertriglyceridemia
Gagnon, C. A., & Ashraf, A. P. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01237-z · Cited by 10
“Combined with fasting, this approach can lead to an 80% reduction in TG within 24 [60].”
BackgroundGenetics of remnant cholesterol
Wulff, A. B., & Nordestgaard, B. G. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000991 · Cited by 8
Li, D., Liu, Z., & Jiang, H. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02862-0 · Cited by 11
“…of three randomized controlled trials (RCTs) involving 207 patients with severe HTG reported that after an average treatment duration of 8.1 months, 84% of volanesorsen-treated patients achieved TG levels below 500 mg/dL, compared to only 35% in the placebo group [90–93]. profiles [64].”
InfluentialFogacci, F., & Cicero, A. F. G. (2026) · Diseases · doi:10.3390/diseases14020047 · Cited by 9
“In the APPROACH trial, the antisense oligonucleotide volanesorsen reduced triglycerides by 77% at 3 months, and 77% of participants achieved triglycerides 750 mg/dL, but intensive platelet monitoring is required because of thrombocytopenia risk [32].”
Peterson, A. L. H., Ashraf, A. P., Bachman, J., Hegele, R. A., Rashad, M., South, A. M., Tran, A. H., Zachariah, J. P. V., & Wong, J. P. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000195 · Cited by 8
Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity
Kim, H. I., DeBoever, C., Walter, K., Kalantzis, G., Li, C., Mozaffari, S. V., Kundu, K., Jacobs, B. M., Mohammadi‐Shemirani, P., Musolf, A. M., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02553-7 · Cited by 12
“%) reported in clinical trials of APOC3 inhibition 55–57 .”
Childhood Hypertriglyceridemia: Is It Time for a New Approach?
Sunil, B., & Ashraf, A. P. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01000-2 · Cited by 9
Krauß, L. U., Brosig, A. M., Schlosser, S., Pavel, V., Mehrl, A., Gülow, K., Kandulski, A., Müller, M., & Schmid, S. A. (2023) · Digestive Diseases · doi:10.1159/000529975 · Cited by 10
“The antisense oligonucleotide volanesorsen signi fi cantly lowered triglyceride levels in patients with familial chylomicronemia syndrome in a randomized trial and reduces the rate of triglyceride-induced pancreatitis in familial chylomi-cronemia by approximately 30% [7, 26].”
Serum Levels of Lipoprotein Lipase Are Increased in Patients with Inflammatory Bowel Disease
Rodríguez-Hernández, O., Palau, M. C., Hernández-Camba, A., Alonso-Abreu, I., Ramos, L., de Armas‐Rillo, L., Martín‐González, C., López‐Mejías, R., González-Gay, M. Á., & Ferraz‐Amaro, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065194 · Cited by 10
“For this reason, therapies aimed at increasing LPL-mediated clearance of triglycerides by decreasing the activity of proteins that inhibit LPL are emerging [11,12].”
BackgroundTargeting host-specific metabolic pathways—opportunities and challenges for anti-infective therapy
Konaklieva, M. I., & Plotkin, B. J. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1338567 · Cited by 8
Atherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies
Omari, M., & Alkhalil, M. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11040126 · Cited by 11
“The first of these drugs is volanesorsen, an antisense oligonucleotide that binds to the apoC-III mRNA and disrupts apoC-III translation, resulting in lower levels of chylomicrons and triglycerides [84].”
BackgroundDiscovery platforms for RNA therapeutics
Ciucci, G., Braga, L., & Zacchigna, S. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16424 · Cited by 8
“…et al., 2017) Inotersen Transthyretin Transthyretin-mediated amyloidosis (Benson et al., 2018) Volanesorsen ApoC-III Familial chylomicronaemia (Witztum et al., 2019) Milasen CLN7 Batten disease (Kim et al., 2019) siRNA Patisiran Transthyretin Familial amyloid polyneuropathy (Adams et al.,…”
Navigating Lipodystrophy: Insights from Laminopathies and Beyond
Krüger, P., Hartinger, R., & Djabali, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158020 · Cited by 11
“Volanesorsen, an antisense oligonucleotide targeting apoC3, has proven highly effective in reducing triglyceride (TG) levels, although it may also cause an increase in LDL levels [146].”
BackgroundKim, A. S., Hakeem, R., Abdullah, A., Hooper, A. J., Tchan, M. C., Alahakoon, T. I., & Girgis, C. M. (2020) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-19-0165 · Cited by 8
Uncovering the role of apolipoprotein C-III in insulin resistance
Aguilar-Recarte, D., Palomer, X., & Vázquez‐Carrera, M. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.09.003 · Cited by 9
Approach to patients with hypertriglyceridemia
Chait, A., & Feingold, K. R. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101659 · Cited by 11
Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances
Atar, D., Langslet, G., & Tonstad, S. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0117 · Cited by 12
Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?
Béliard, S., Mourre, F., & Valéro, R. (2024) · Diabetologia · doi:10.1007/s00125-024-06100-z · Cited by 10
“…oligo-nucleotide targeting hepatic apoC-III, was first studied in the APPROACH and COMPASS Phase III trials in individuals with familial chylomicronaemia syndrome (FCS) [52] and in individuals with multifactorial chylomicronaemia syndrome (MCS), including 40% of participants with diabetes [53].”
BackgroundQuilomicronemia familiar y quilomicronemia multifactorial
Muñiz-Grijalvo, O., & Díaz-Díaz, J. L. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.011 · Cited by 9
Targeting triglycerides to lower residual cardiovascular risk
Bubb, K. J., Nelson, A. J., & Nicholls, S. J. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2058489 · Cited by 9
Genome Editing in Dyslipidemia and Atherosclerosis
Chen, Z., Lehertshuber, C., & Schunkert, H. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_10 · Cited by 8
Dimmeler, S., Ferri, L. D. A. F., Nioi, P., O’Donnell, C. J., Damy, T., Gómez‐Outes, A., Giacca, M., Guo, W., Kavousi, M., Kupatt, C., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf041 · Cited by 7
Peng, X., Lian, Z., O’Brien, V., Xiao, J., Litchfield, B., Perrard, X. D., Lu, X., Ni, J., Mukherjee, A., Simmons, T., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100763 · Cited by 8
Course of Pregnancies and Occurrence of Acute Pancreatitis in Women With Chylomicronemia
Larouche, M., Bergeron, J., Brisson, D., Laflamme, N., Audet-Verreault, N., Sharon, C., Charrière, S., Rama, M., Collin‐Chavagnac, D., Moulin, P., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf409 · Cited by 9
Self-citationYang, X., Alexander, V. J., Xia, S., & Tsimikas, S. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120462 · Cited by 7
Self-citationPharmacotherapy of cardiovascular diseases from herbs and pills to nucleic acids
Landmesser, U., Thum, T., Tokgözoğlu, L., Guzik, T. J., Cosentino, F., Hajjar, R. J., Gonçalves, A., Laguna-Fernández, A., Nioi, P., Prochaska, J. H., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf520 · Cited by 7
Jang, S. H., Roh, J. W., Oh, K. S., Joo, S. Y., Kim, J. A., Kim, S. J., Choi, J. Y., Jung, J., Kim, Y., Bok, J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.044 · Cited by 7
Genetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review
Luca, C. D., Ciciola, P., D’Errico, G., Taranto, M. D. D., Fortunato, G., Gross, C., Garn, J., Iannuzzo, G., Minno, M. N. D. D., & Calcaterra, I. L. (2025) · Genes · doi:10.3390/genes16111377 · Cited by 9
“The APPROACH and COMPASS trials, as well as pooled analyses, consistently demonstrated 70–80% reductions in TG levels with volanesorsen, confirming its efficacy in patients with absent or severely impaired LPL activity [4,39].”
RNA-based drugs: current, imminent and possible therapeutic applications
Torrisi, S. A., Geraci, F., Diolosà, L., Luca, A. D., Falzone, L., Drago, F., Libra, M., & Leggio, G. M. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108958 · Cited by 11
Björnson, E., Adiels, M., Taskinen, M., Packard, C. J., & Borén, J. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01399-y · Cited by 9
“…syndrome (FCS), which is caused by a genetic deficiency of LPL. Treatment with an antisense oligonucle - otide that targets apoC-III, led to a significant reduction in serum triglyceride levels, confirming that apoC-III hinders remnant clearance beyond its role in lipolysis [44, 45].”
Bazarbashi, N., & Miller, M. J. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.11.006 · Cited by 10
Zhang, Y., Jiang, Z., Chen, L., Lei, T., & Zheng, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05359-5 · Cited by 7
“Volanesorsen is a novel antisense oligonucleotide inhibitor of APOC3 mRNA developed for the treatment of familial chylomicronemia syndrome [54, 55].”
BackgroundSchwartz, G. G., Szarek, M. J., Reijnders, E., Jukema, J. W., Bhatt, D. L., Bittner, V., Fazio, S., Garon, G., Goodman, S. G., Harrington, R. A., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf067 · Cited by 8
RNA Therapies in Cardio-Kidney-Metabolic Syndrome: Advancing Disease Management
Mohammadi, A., Karimian, A., Shokri, K., Mohammadi, A., Karzar, N. H., Bahar, R., Radfar, A., Pakyari, M., & Tehrani, B. N. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10603-4 · Cited by 8
“Volanesorsen, an ASO targeting apolipoprotein C-III (ApoC-III), effectively lowers triglyceride (TG) levels by promoting the breakdown of apoC-III mRNA, thereby enhancing TG clearance [14].”
Engell, A. E., Bathum, L., Siersma, V., Andersen, C. L., Lind, B., & Jørgensen, H. L. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02607-5 · Cited by 7
“Some of these drugs in development have already shown positive results, significantly reducing remnant cholesterol and plasma triglycerides [61].”
Watts, L. M., Karwatowska‐Prokopczuk, E., Hurh, E., Alexander, V. J., Balogh, K., O'Dea, L. S. L., Geary, R. S., & Tsimikas, S. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0837 · Cited by 9
“In May 2019, volanesorsen (Waylivra (cid:2) ) was approved for clinical use in patients with FCS by the European Medicines Agency [9].”
Self-citationManaging of dyslipidaemia characterized by accumulation of triglyceride-rich lipoproteins
Visser, J., van Zwol, W., & Kuivenhoven, J. A. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00979-y · Cited by 7
Nucleic acid therapy in pediatric cancer
Li, Y., Huang, B., Xue, Z., Gao, Y., & Zhuo, Z. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106441 · Cited by 8
Innate Immunity in Cardiovascular Diseases—Identification of Novel Molecular Players and Targets
Poller, W. C., Heidecker, B., Ammirati, E., Kuss, A. W., Tzvetkova, A., Poller, W. C., Skurk, C., & Haghikia, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010335 · Cited by 8
Posicionamento Brasileiro sobre Síndrome da Quilomicronemia Familiar – 2023
Izar, M. C. D. O., Santos, R. D., Assad, M. H. V., Chagas, A. C. P., Toledo, A. D. O., Nogueira, A. C. C., Souto, A. C. C. F., Lottenberg, A. M., Chacra, A. P. M., Ferreira, C. E. D. S., et al. (2023) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20230203 · Cited by 9
Xu, Y., Guo, J., Zhang, L., Miao, G., Lai, P., Zhang, W., Liu, L., Hou, X., Wang, Y., Huang, W. Y., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.840358 · Cited by 9
“These findings demonstrated that loss of ApoC3 still attenuated severe HTG in the setting of severe refractory hypercholesterolemia in female FH hamster model after lipid-rich diet challenge, indicating that sex hormone could potentially contribute to lowering TG. Interestingly, in patients with FCS caused by loss-of-…”
BackgroundInfluentialFocus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine
Tessier, N., Moawad, F., Amri, N., Brambilla, D., & Martel, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081200 · Cited by 9
“FCS Volanesorsen (NCT02211209) ASO ApoC3 Approved 300 mg once/week Phase III: reduction in mean plasma APOC3 and TG level [137]”
BackgroundAshraf, T., Devi, N., Aradhna, F., Devi, S., Nancy, F., Kumar, A., Ameer, F., Absar, F., Kumar, L., Kumar, S., et al. (2025) · Annals of Medicine & Surgery · doi:10.1097/ms9.0000000000003505 · Cited by 6
“This is in contrast to volanesorsen, another antisense oligonucleotide targeting APOC3, which was associated with thrombocytopenia and bleeding complications [ 48 ] .”
Tian, Z., Luo, H., Chu, Y., Liu, Y., Gao, S., Song, L., Yang, Z., & Liu, D. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01513-4 · Cited by 6
“RNAi-based therapeutics for APOC3 gene silencing are currently approved or in clinical trials [18], including the ASO drug volanesorsen [19], the GalNAc-conjugated ASO drug olezarsen [20], and the GalNAc–siRNA drug plozasiran [21].”
Maidman, S. D., & Rosenson, R. S. (2025) · BioDrugs · doi:10.1007/s40259-025-00731-3 · Cited by 8
“…with FCS, a rare autosomal recessive condition in which severe hypertriglyceridemia results from complete lack of LPL activity due to biallelic germline pathogenic variants, in APPROACH (Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome) [66].”
InfluentialWang, J., Qu, J., Ye, M., Feng, R., Hui, X., Yang, X., Jin, J., Tong, Q., Zhang, X., & Wang, Y. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101416 · Cited by 9
Remnant Cholesterol: From Pathophysiology to Clinical Implications in Type 1 Diabetes
Sebastián‐Valles, F., Muñiz, Á. M., & Marazuela, M. (2025) · Endocrines · doi:10.3390/endocrines6030046 · Cited by 6
“Although approved for the treatment of familial chylomicronemia syndrome, its use in multifactorial dyslipidemias has been limited by adverse effects such as severe thrombocytopenia [40].”
Tang, Y., Zou, J., Li, Q., Liu, Y., Guo, X. D., Bai, H., He, X. D., Gan, C., Zhao, X., Wu, W., et al. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126189 · Cited by 8
Miteva, K., Buhayer, A., Follonier, C., & Mach, F. (2025) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001777 · Cited by 6
Reijnders, E., Bossuyt, P. M., Jukema, J. W., Ruhaak, L. R., Romijn, F. P. H. T. M., Szarek, M. J., Trompet, S., Bhatt, D. L., Bittner, V., Díaz, R., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.322336 · Cited by 7
Designing nucleic acid-based therapeutics for cancer treatment: Updates on the state of the art
Peng, B., Jayasinghe, M. K., Le, A. H., Tran, N. M., & Le, M. T. N. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.041 · Cited by 12
Toth, P. P., & Banach, M. (2025) · Archives of Medical Science · doi:10.5114/aoms/216960 · Cited by 9
“Volanesorsen achieved a 77% TG reduction (mean absolute reduction of 1712 mg/dl) vs. +18% increase with placebo ( p < 0.001); 77% FCS patients reached TG < 750 mg/dl vs. 10% in the placebo group [102].”
InfluentialPradhan, A. K., Thandi, P., Mahajan, K., Iellamo, F., Perrone-Filardi, P., & Perrone, M. A. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.059 · Cited by 6
Bardawil, S. A., Barthélémy, P., & Ferey, L. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c06656 · Cited by 8
Genetic determinants of pancreatitis risk in hypertriglyceridemia
Paquette, M., Guay, S., & Baass, A. W. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000962 · Cited by 6
An up-to-date review of emerging biologic therapies for hypercholesterolemia
Tomlinson, B. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2442455 · Cited by 6
“It was used in phase 3 studies in patients with FCS (APPROACH study) [46], in patients with multifactorial chylomicronemia (COMPASS study) [47], and patients with familial partial lipodystrophy (BROADEN) [48].”
New therapeutic approaches for the treatment of hypertriglyceridemia
Gouni‐Berthold, I., & Schwarz, J. (2022) · Herz · doi:10.1007/s00059-022-05113-x · Cited by 6
“The APPROACH trial investigated the effect of volanesorsen (300mg administered subcutaneously once a week) versus placebo on TG levels in 66 patients with familial hyperchylomicronemia syndrome (FCS), a rare genetic disease caused by loss of the activity of LPL and characterized by sHTG and chylomicronemia as well as…”
BackgroundKhalifeh, M., Santos, R. D., Oskuee, R. K., Badiee, A., Aghaee‐Bakhtiari, S. H., & Sahebkar, A. (2022) · Progress in Lipid Research · doi:10.1016/j.plipres.2022.101197 · Cited by 7
The era of targeted therapy for hyperlipidemia
Чубыкина, У. В., Tyurina, A. V., & Владиславович, Е. М. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6038 · Cited by 6
Therapieempfehlungen bei Fettstoffwechselstörungen: Die neue Leitlinie von 2019
Vogt, A., & Weingärtner, O. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1199-8193 · Cited by 6
“Hierunter werden die Triglyzeride um etwa 70% gesenkt [26].”
BackgroundTriglyzeride – Aktuelle Bewertung als Risikomarker und Therapieziele
Merkel, M., Müller‐Wieland, D., Laufs, U., & Parhofer, K. G. (2022) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1516-2661 · Cited by 8
Harnessing nucleic acid technologies for human health on earth and in space
Sarli, S. L., & Watts, J. K. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.08.006 · Cited by 6
“Two ASO gapmers are currently in clinical use: inotersen, for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) (Benson et al. 2018) and volanesorsen, for the treatment of familial chylomicronemia syndrome (Witztum et al. 2019), with many more in late stage clinical trials.”
A novel mouse model of familial combined hyperlipidemia and atherosclerosis
Chen, M.-J., Xu, Y.-T., Sun, L., Wang, Z.-H., Little, P. J., Wang, L., Xian, X.-D., Weng, J.-P., & Xu, S.-W. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01241-8 · Cited by 5
“Volanesorsen, a novel antisense oligonucleotide (ASO) targeting ApoC3 [13], effectively lowers TG levels in individuals with hyperlipidemia as found in the results of a phase 3 clinical trial [14].”
Chemical Insights into Oligonucleotide–Protein Binding for Therapeutic Applications
Gupta, S., Gupta, A., Mukherjee, M., Bose, S., & Sinha, S. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00427 · Cited by 6
Epigenetic Regulation and Therapeutic Targeting of Alternative Splicing Dysregulation in Cancer
Yan, L., & Lai, M. (2025) · Pharmaceuticals · doi:10.3390/ph18050713 · Cited by 6
Henry, D., Baugé, E., Staels, B., & Lalloyer, F. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100086 · Cited by 5
Dysregulated Lipid Metabolism as a Central Driver of Atherosclerotic Plaque Pathology
Steinbeck, J. E., Iannotti, R. A., & Rasheed, A. (2025) · Lipidology · doi:10.3390/lipidology2040017 · Cited by 6
“Two approved antisense oligonucleotides targeting Apo-C3, Volanesorsen and Olezarsen, have shown reductions in circulating triglycerides, Apo-B, and non-HDL cholesterol [280–282].”
Wadström, B. N., Pedersen, K. M., Wulff, A. B., & Nordestgaard, B. G. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70005 · Cited by 6
“Finally, novel gene‐silencing therapies targeting apolipoprotein C3 and angiopoietin‐like protein 3, which have large remnant cholesterol‐lowering effects, are to be tested in cardiovascular outcome trials [43–49].”
Jeong, J., Rastogi, A., Kim, T., Henry, S. P., Hoffmaster, C. M., Kim, S. Y., Kim, W., Lee, S.-Y., Park, J., Wi, I.-S., et al. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2024.0057 · Cited by 6
“41,42 Here, we present a non-clinical reproductive toxicology study with ISIS 838707, a murine-speci fi c GalNAc-conjugated ASO designed to lower mouse ApoC-III mRNA levels, leading to reduced TG levels.”
Weijs, B. M., Oostveen, R. F., Kraaijenhof, J. M., & Stroes, E. S. G. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000906 · Cited by 5
“Emerging therapies include RNA-targeted interventions aimed at apolipoprotein C-III (apoC-III) and angiopoietin-like-3 (ANGPTL3) [10,11 & triglyceride levels in phase 2 clinical trials [15,16].”
Self-citationDrug Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome: Focus on Volnesorsen
Gesner, M., & Frishman, W. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000468 · Cited by 4
“Once again, it is believed that this effect also will not play a role in patients with FCS.”
InfluentialMasson, W. M., Barbagelata, L., Fleitas, M., Herzkovich, N., Kerschner, E., Rossi, E., Siniawski, D. A., Ami, M. V., & Nogueira, J. P. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000601 · Cited by 6
“Volanesorsen is an antisense oligonucleotide inhibitor of apoC-III designed to reduce the production of apoC-III and its efficacy was demonstrated in two recently published clinical trials (38,39).”
BackgroundRecent Updates on Epigenetic-Based Pharmacotherapy for Atherosclerosis
Ariyanto, E. F., Wijaya, I., Pradian, Z. A., Bhaskara, A. P. M., Rahman, P. H. A., & Oktavia, N. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s463221 · Cited by 6
“63–70,85 target miRNAs and block their functions, such as antagomiRs, and lock”
BackgroundApolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen
Valdivielso, P., & Coca Prieto, I. (2024) · Med · doi:10.1016/j.medj.2024.05.004 · Cited by 5
Makhmudova, U., Schulze, P. C., Lorkowski, S., März, W., Geiling, J. A., & Weingärtner, O. (2024) · Journal of Medical Case Reports · doi:10.1186/s13256-024-04532-0 · Cited by 5
“In the phase 3 randomized controlled trial APPROACH, volanesorsen showed a 77% reduction in TG levels among patients with FCS [30].”
BackgroundAntisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials
Ogieuhi, I. J., Callender, K., Odukudu, G.-D. O., Obi, E. S., Muzofa, K., Babalola, A. E., Ugiomoh, O. M.-A., Umenzeakor, K. H., Akingbola, A., Ayoson, C. O., et al. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00682-w · Cited by 5
Bouvenot, G. (2022) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2022.02.005 · Cited by 8
Update Lipidologie: Evidenzbasierte Behandlung von Fettstoffwechselstörungen
Parhofer, K. G. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01536-8 · Cited by 9
“Volanesorsen kann die Triglyzeridspiegel deutlich reduzieren unddasPankreatitisrisikovermindern[33].”
Expanding therapeutic options: overview of novel pharmacotherapies for dyslipidemia
ALGhasab, N. S., Fogacci, F., Арманович, А. А., & Cicero, A. F. G. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2406270 · Cited by 5
“These drugs effectively lower chylomicrons and TG levels in the body by disrupting apoC-III translation [20].”
InfluentialFine‐grained authorization for job execution in the Grid: design and implementation
Keahey, K., Welch, V., Lang, S. J., Liu, B., & Meder, S. (2004) · Concurrency and Computation Practice and Experience · doi:10.1002/cpe.827 · Cited by 5
Alam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., et al. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02337-1 · Cited by 4
“In the APPROACH trial, a phase III study that enrolled patients with FCS volanesorsen lowered TG levels by approximately 77% from baseline compared to placebo [ 44 ].”
Baragetti, A. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.09 · Cited by 5
Unanticipated Enhancement of Intestinal TG Output by Apoc3 ASO Inhibition
Syed‐Abdul, M. M., Tian, L., & Lewis, G. F. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319765 · Cited by 4
Andersson, D. P., Littmann, K., Kindborg, G., Eklund, D., Sejersen, K., Yan, J., Hogling, D. E., Parini, P., & Brinck, J. W. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae010 · Cited by 4
“…has been shown to be very efficient in reducing plasma triglyceride levels in patients with familial chylomicronaemia syndrome and with severe hTG. 24,25 Furthermore, angiopoietin-like (ANGPTL) protein family, including ANGPTL 3, 4, and 8, is another important target through their function as…”
BackgroundDiagnosis, Evaluation, and Management of Severe Hypertriglyceridemia
Krishnamurthy, A., Homan, E. A., & Kim, S. M. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00758-9 · Cited by 5
“No major bleeding events occurred [53].”
Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors
Mansoor, T., Nambi, V., Parikh, S. S., Misra, A., Ismayl, M., Sullivan, C., Sperling, L. S., Virani, S. S., Rifai, M. A., Koshy, S. K. G., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00748-7 · Cited by 4
“FCS has an estimated prevalence of 1–10 per 1 million in the USA, and is characterized by severely elevated TG levels often exceeding 1000 mg/dL secondary to decreased or absent LPL activity due to either inactivating mutations of the LPL gene or other proteins involved in LPL function [18, 20].”
Rare variant genetic landscape of familial chylomicronemia syndrome (FCS) in the United Kingdom
Bashir, B., Forrester, N. A., Downie, P., Marsh, S., Dent, C. E., Wierzbicki, A. S., Dawson, C., Schofield, J. D., Jenkinson, F., Mansfield, M. W., et al. (2025) · Genetics in Medicine Open · doi:10.1016/j.gimo.2025.103445 · Cited by 7
“9 With the advent of specific drug therapies for FCS 36 and the anticipated introduction of additional treatments, 15 it is crucial to prevent delays in molecular diagnosis, which is often necessary for eligibility for disease-modifying therapies.”
Self-citationObeng, E., Ergashev, A., Yao, Q., Wu, W., & Chen, G. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s514653 · Cited by 4
Bharaj, I. S., Purewal, K., Munaim, J., Brar, A. S., Kacheria, A., Simister, A., Thirupathy, U., Gupta, P., Kahlon, J., Thwe, E. E., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13092192 · Cited by 7
“While originally developed for rare conditions such as familial chylomicronemia syndrome (FCS), its mechanism is also relevant to the broader population with severe hypertriglyceridemia, a more common and clinically significant group [20,21].”
Joubert, S., Ninan, J., Rosario, N., Davis, S. R., Wollen, J. T., & Wang, E. M. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00774-5 · Cited by 4
Chu, X., Biao, Y., Li, H., Chen, J., Yin, J., Gao, X., Wang, S.-L., Ma, J., Yi, L., Zhang, Y., et al. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02782-5 · Cited by 4
“Approved drugs include volanesorsen (Waylivra), which effectively lowers triglyceride levels and reduces the risk of pancreatitis [76].”
Metadata
- Authors
- Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., Stroes, E. S. G., Bergeron, J., Soran, H., Civeira, F., Hemphill, L., Tsimikas, S., Blom, D. J., O’Dea, L., & Bruckert, E.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- From the Department of Medicine, University of California San Diego, La Jolla (J.L.W., S.T.), and Ionis Pharmaceuticals, Carlsbad (V.J.A., Q.Y., S.G.H., R.S.G., S.T.) — both in California; the Department of Medicine, Université de Montréal and ECOGENE 21, Chicoutimi, QC (D.G.), and the Department of Medicine and Laboratory Medicine, Centre Hospitalier Universitaire de Québec–University Laval, Quebec, QC (J.B.) — both in Canada; the Department of Medicine, Beth Israel Deaconess Medical Center (S.D.F....
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-08-08
- Volume
- 381
- Issue
- 6
- Pages
- 531-542
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2966503756
- Semantic Scholar
- 1b419fba1e6af00f305b1f8b0ee92c239fec7d40
- Cited by
- 669
- References
- 34
- Citations by year
- 2026: 88 · 2025: 112 · 2024: 112 · 2023: 77 · 2022: 95 · 2021: 91 · 2020: 79 · 2019: 14
- FWCI
- 50.23
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Zaguan (University of Zaragoza Repository) (submittedVersion)
- Funders
- Akcea Therapeutics
- Ionis Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Keywords
- volanesorsen, familial chylomicronemia syndrome, apolipoprotein C-III, triglyceride levels, antisense therapy, hypertriglyceridemia, injection site reactions, platelet count, treatment efficacy and safety, triglyceride lowering
- MeSH terms
- Adult, Aged, Analysis of Variance, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Hyperlipoproteinemia Type I, Male, Middle Aged, Oligonucleotides, Platelet Count, RNA, Messenger, Thrombocytopenia, Triglycerides, Apolipoprotein C-III, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.